RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望...市場調査レポートについてご紹介

【英文タイトル】RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report

3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases – Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases – Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders – Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease – Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)

4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025

5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025

6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company’s Market Position
6.2.3.2 Arrowhead Acquires Novartis’ RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia’s CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics’ RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest

7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline

8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry’s Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors

9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics’ RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech’s RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics

10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?

11. Glossary


【レポート販売概要】

■ タイトル:RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望
■ 英文:RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches
■ 発行日:2015年6月
■ 調査会社:visiongain
■ 商品コード:VGAIN50611
■ 調査対象地域:グローバル
  • 玩具・ゲームの世界市場2017-2021
    ABSTRACTAbout Toys and Games Toys and games are used for the amusement and entertainment of children. Activity toys such as building sets, dolls, puzzles such as jigsaw puzzles, and card games help children enhance their mental agility and develop coordination and manual skills. The increasing consumer demand for branded toys and games, the growing willingness of parents to spend more on such prod …
  • 世界のC型肝炎治療薬市場(2014-2018)
    About Hepatitis C Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule envelop …
  • 民間航空機用アビオニクスの世界市場2015-2019
    About Commercial Aircraft Avionics Systems Avionics are electronics systems used in aircraft for communication, navigation, and various other flight critical applications. Avionics are one of the most expensive and highly critical components in modern aircraft. Modern avionics also aid in improved navigation and routing, provide enhanced situational awareness to pilots, and improve the ATM process …
  • 生体吸収性ステントの世界市場:材料(ポリマー、金属)、処置、吸収速度、薬品、用途、需要先、地域別分析
    The global bioabsorbable stents market is expected to reach USD 2.4 Billion by 2021 from USD 0.4 Billion by 2016, at a CAGR of 42.5% during the forecast period. The major driving factors are the increasing focus of the companies on clinical trials of bioabsorbable stents, increasing aging population, technological advancements, and patients’ preference for minimally invasive therapies. However, fa …
  • 電気通信産業分野におけるAI(人工知能)の世界市場2019-2023
    About this market Maintenance of equipment such as mobile towers in the telecommunication industry is one of the key factors that can enhance equipment performance and enable cost saving. Service providers in this industry must be able to effectively monitor their equipment and infrastructure such as servers in data centers and set-top boxes to ensure a secure and reliable network. Maintaining the …
  • 光ネットワーク及び光通信デバイスの世界市場:光ファイバー、光増幅器、光スイッチ、光スプリッター、光ファイバーサーキュレーター等
    Optical networking and communications for this market study is as follows, a type of communications network wherein data transmission occurs via light as optical or Infra-Red signals and optical components form the building blocks of the network. The market has been defined as the summation of hardware and services revenues. The study captures the industry trends in the optical networking and comm …
  • アメリカのStorage-as-a-Service(クラウドストレージサービス)市場
    About STaaS Storage-as-a-service (STaaS) is flexible and enables service providers to efficiently deploy automated services for managing, recovering, and archiving data. In a STaaS model, enterprises lease their storage infrastructure to a cloud service provider (CSP) to store their business data. Service level agreements (SLAs) are signed between the concerned parties to facilitate this migration …
  • BIOMET 3i, Inc.:市場シェア分析
    BIOMET 3i, Inc. Market Share Analysis Summary GlobalData’s new report, “BIOMET 3i, Inc. Market Share Analysis” provides in-depth information on BIOMET 3i, Inc.’s market position in the different medical equipment markets it operates in. The report provides BIOMET 3i, Inc. market share information in two key market categories – Dental Implants and Dental Biomaterials. The report also provides data …
  • インメモリー・コンピューティングの世界市場2016-2020
    About In-Memory Computing In-memory computing is a database management technology that stores data in the random access memory (RAM) of servers rather than in traditional disks. It is estimated to be 3,000 times faster than rotating disks. In-memory computing helps in faster data management, as the data to be processed is already stored in computer's main memory. Technavio’s analysts forecast the …
  • ロボット式薬局用調剤機器の世界市場2017-2021
    About Robotic Pharmacy Dispensing Systems Dispensing comprises processes from receiving a prescription to issuing the medicines. It is an essential process in patient care in healthcare facilities as all other processes prior to prescription dispensing will be redundant, if the medication has errors such as incorrect dosage or inappropriate packaging. As hospitals and retail pharmacies increase th …
  • スペインのウイルス・細菌検査市場
    Complete report $6,700.  DataPack (test volumes, sales forecasts, supplier shares) $4,300.“Emerging Opportunities in the Spanish Virology and Bacteriology Testing Market” is a new strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years.  The report examines key Spanish market trends; reviews current …
  • ソフトウェアライセンス管理の世界市場2016-2020
    About the Software license management The major drivers for the adoption of software licensing are piracy and malware. Software licensing acts as an agreement to solve these issues. It provides the rights to use packaged software or components of software. The use of a software without proper licensing would constitute an infringement of copyright laws. All enterprise applications are offered to e …
  • Athabasca Oil Corporation:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Athabasca Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Athabasca Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
  • 自動車X-by-Wireシステムの世界市場:シフト・バイ・ワイヤ、スロットル・バイ・ワイヤ、サスペンション・バイ・ワイヤ、パーク・バイ・ワイヤ
    Since the inception of the automobiles in the year 1886 by Karl Benz, vehicle operations have taken a big leap as the carriage used in the first car was a horse buggy. Steam engines were used in earlier times in order to power the automobiles which were later replaced by internal combustion engine. The turning point for the automobile industry was the introduction of line production by Henry ford, …
  • 3D印刷サービスの世界市場2015-2019
    About 3D Printing Services Over the years, enterprises around the world have become increasingly dependent on various advanced technologies to run their business and drive revenue growth. This trend is expected to intensify, which in turn would increase the importance of adoption of new technologies such as 3D printing. 3D printing technology is one of the most promising technologies among various …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。